Latest Targeted therapy Stories
A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care. “We’re in a new paradigm in which we realize this top cause of cancer deaths is actually a number of related diseases, each potentially with its own cause and cure,” Bunn says. The review describes the shift from blanketing lung...
CAMBRIDGE, Mass., Dec. 10, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced Phase I clinical trial results for MM-302, the company's novel agent for the treatment of advanced HER2 positive (HER2+ or ErbB2+) breast cancer. The findings demonstrated preliminary safety and tolerability. A study of its potential companion imaging diagnostic was shown to predict treatment response in preclinical models. Data were presented at the 2012 CTRC-AACR San...
MISSISSAUGA, ON, Dec. 10, 2012 /CNW/ - Roche today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta® (pertuzumab), Herceptin® (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo. Results showed that the risk of death was reduced by 34 percent...
Research presented at 2012 SABCS examines cardiac safety profile of MM-302, a new HER2-targeted Liposomal Doxorubicin Agent. CAMBRIDGE, Mass., Nov. 27, 2012 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented at the 2012 CTRC-AACR San Antonio Breast...
MONTCLAIR, N.J., Nov. 26, 2012 /PRNewswire/ -- MetaStat, Inc. ("MetaStat" or the "Company") (OTCBB: MTST) today announced the October 31, 2012 online publication of "Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients" in Breast Cancer Research, an international, peer-reviewed online journal. Dr. John S. Condeelis, Chairman of MetaStat's Scientific Advisory Board, is senior on the publication. Dr. Condeelis holds...
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial. The treatment of gastrointestinal stromal tumor, or GIST, even in its advanced metastatic stage, has been dramatically improved with two oral targeted drugs – imatinib (Gleevec) and...
NORWALK, Conn., Nov. 16, 2012 /PRNewswire/ -- UBM Medica US announces that Cancer Network and the journal ONCOLOGY are presenting a two part primer report on targeted therapies in solid tumors. Targeted therapy has become both the centerpiece of the current era in cancer therapeutics and the foundation of the field's hope for future progress. Although the initial successes of targeted therapies occurred in hematologic malignancies, recent years have seen a string of promising results...
ROCKVILLE, Md., Nov. 14, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and nine-month periods ending September 30, 2012. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) EntreMed reported a net loss for the third quarter of 2012 of ($1.2 million), or ($0.05) per share. This compares with a net loss of ($1.3 million), or...
WASHINGTON, Nov. 8, 2012 /PRNewswire-USNewswire/ -- LUNGevity Foundation, the nation's largest lung cancer-focused nonprofit, and Take Aim at Cancer, a leading supporter of targeted therapy-focused lung cancer research and education, have agreed to collaborate to drive funding for lung cancer research and elevate awareness about the nation's number one cancer killer. The two lung cancer nonprofits are joining together initially to hold a series of fundraising and awareness events...
MARTINSRIED, Germany and MUNICH and MONROVIA, Calif., Nov. 5, 2012 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based Xencor, Inc. today announced the online publication of first clinical data on the anti-CD19 antibody MOR208 (MOR00208/XmAb5574) in the American Society of Hematology Annual Meeting Abstracts issue of the peer-reviewed medical journal Blood. MOR208 showed encouraging signs of preliminary anti-tumor activity and an acceptable...
